Evaluation of iron chelator administration, and cochlear implantation for superficial siderosis - ECHACISS

Sanjo Nobuo0 个研究点目标入组 50 人开始时间: 2019年3月27日最近更新: 2024年1月22日

试验速览

暂无简介。

•1) Patients who manifest a triad (hearing loss, cerebellar ataxia, myelopathy), and show characteristic brain hemosiderin deposit and cerebellar atrophy on brain MRI, and is diagnosed as Superficial Siderosis. Cessation of bleeding into the cerebrospinal fluid has been confirmed by treatment, such as surgical operation or oral administration. Patients whose symptom progression is objectively confirmed. The duration of disease does not matter (regardless of gender).
•2) Patients who aged 20 years or older at the time of acquiring consent, and obtained document consent from the patient.
•3) Patients who do not have abnormal findings such as leukopenia and liver dysfunction by blood test.
•4) Clinical data for follow-up among patients who do not agree with the oral administration of a chelator, and agree to use their data will be target patient group.

•1) Patients with a history of hypersensitivity to deferiprone or other an iron chelator.
•2) Patients taking internal medication or drip medication with side effects of leukopenia.
•3) Pregnant women or patients who may be pregnant, lactating patients or patients wishing for pregnancy during the study period.
•4) Patients who have difficult MRI imaging such as claustrophobia.
•5) In addition, patients who are judged inappropriate to be included in the study by an investigator or a test sharing doctor.

发起方

Sanjo Nobuo